Results 11 to 20 of about 41,938 (307)
Design and Production of Bispecific Antibodies [PDF]
Antibodies, 2019 With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy.
Qiong Wang +7 more
doaj +3 more sources
Bispecific antibodies for viral immunotherapy [PDF]
Human Vaccines & Immunotherapeutics, 2017 Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura +2 more
doaj +3 more sources
Hematology, 2023 Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique +2 more
openaire +3 more sources
Bispecific antibodies and their applications [PDF]
Journal of Hematology & Oncology, 2015 Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Fan, Gaowei +3 more
openaire +2 more sources
The making of bispecific antibodies [PDF]
mAbs, 2017 During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG ...
Brinkmann, Ulrich, Kontermann, Roland E.
openaire +2 more sources
Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. [PDF]
PLoS ONE, 2018 Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression.
Yumei Li +8 more
doaj +1 more source
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
mAbs, 2023 Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain of CAP256V2LS,
Baoshan Zhang +27 more
doaj +1 more source
A new approach to produce IgG4-like bispecific antibodies
Scientific Reports, 2021 While achieving rapid developments in recent years, bispecific antibodies are still difficult to design and manufacture, due to mispair of both heavy and light chains. Here we report a novel technology to make bispecific molecules.
Caizhi Zhao +5 more
doaj +1 more source
Modelling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion [PDF]
, 2016 We have developed a mathematical framework for describing a bispecific monoclonal antibody interaction with two independent membrane-bound targets that are expressed on the same cell surface.
Argungu, Maryam +8 more
core +1 more source